Printer Friendly

Credit Suisse retains Low AA credit rating on Roche.

M2 PHARMA-October 14, 2011-Credit Suisse retains Low AA credit rating on Roche(C)2011 M2 COMMUNICATIONS

14 October 2011 - Credit Suisse confirmed yesterday the Low AA credit rating with a "stable" outlook on Roche (VTX:ROG) after the Swiss company announced its revenue for the first nine months of 2011.

Credit Suisse said that the rating is based on the firm's strong business and financial profile. Despite the challenging environment, Roche's performance is solid. Main revenue contributors are oncology medicines such as Herceptin and MabThera as well as eye care product Lucentis and rheumatism drug Actemra.

Credit Suisse retained its "hold" recommendation on Roche's 2.5% bond due in 2012 and on the 4.5% bond due in 2017.

((Comments on this story may be sent to

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Oct 14, 2011
Previous Article:MediciNova to get USD2.5m from Kissei to expand MN-221 programme.
Next Article:Beijing CDC selects Sinovac to supply Anflu for Beijing vaccination campaign.

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters